FOXP3 antibody [C3], C-term

Chikaishi W, Higashi T, Hayashi H, et al. Adiponectin-expressing Treg-containing T cell fraction inhibits tumor growth in orthotopically implanted triple-negative breast cancer. Thorac Cancer. 2023,14(30):3058-3062. doi: 10.1111/1759-7714.15102

Chikaishi W, Higashi T, Hayashi H, et al. Potential activity of adiponectin-expressing regulatory T cells against triple-negative breast cancer cells through the cell-in-cell phenomenon. Thorac Cancer. 2023,14(20):1941-1945. doi: 10.1111/1759-7714.14940

Hanamatsu Y, Saigo C, Takeuchi T. Adiponectin-expressing Treg cells in experimental thymic tumor model. Thorac Cancer. 2023,14(4):432-433. doi: 10.1111/1759-7714.14792

Yen YT, Chien M, Wu PY, et al. Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response. Nat Commun. 2021,12(1):7297. doi: 10.1038/s41467-021-27620-x

Rana MN, Lu J, Xue E, et al. PDE9 Inhibitor PF-04447943 Attenuates DSS-Induced Colitis by Suppressing Oxidative Stress, Inflammation, and Regulating T-Cell Polarization. Front Pharmacol. 2021,12:643215. doi: 10.3389/fphar.2021.643215

Ko M, Kamimura K, Owaki T, et al. Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver. Dis Model Mech. 2021,14(3). doi: 10.1242/dmm.048922

Zhang L, Li Q, Xu J, et al. Cimetidine promotes STUB1-mediated degradation of tumoral FOXP3 by activating PI3K-Akt pathway in gastric cancer. Ann Transl Med. 2020,8(20):1304. doi: 10.21037/atm-20-6070

Jin X, Lin T, Yang G, et al. Use of Tregs as a cell-based therapy via CD39 for benign prostate hyperplasia with inflammation. J Cell Mol Med. 2020,24(9):5082-5096. doi: 10.1111/jcmm.15137

Nguyen DJM, Theodoropoulos G, Li YY, et al. Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer. Mol Cancer Res. 2020,18(1):105-117. doi: 10.1158/1541-7786.MCR-19-0239